Here’s how analysts see Jazz Pharmaceuticals plc (NASDAQ:JAZZ) after this past week.

April 17, 2018 - By Ellis Scott

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) LogoInvestors sentiment increased to 1.09 in 2017 Q4. Its up 0.06, from 1.03 in 2017Q3. It is positive, as 30 investors sold Jazz Pharmaceuticals plc shares while 89 reduced holdings. 49 funds opened positions while 81 raised stakes. 52.98 million shares or 1.12% less from 53.58 million shares in 2017Q3 were reported.
Hillsdale Invest Inc stated it has 300 shares or 0.01% of all its holdings. Mitsubishi Ufj Tru And Bk Corporation holds 120,308 shares or 0.03% of its portfolio. 5,700 were reported by Sit Assocs. Victory Mgmt stated it has 10,848 shares. Swiss Fincl Bank invested in 0.03% or 221,100 shares. 477 are owned by Mckinley Cap Mgmt Limited Liability Delaware. Andra Ap holds 0.04% or 11,900 shares. Condor Capital Mngmt owns 9,015 shares for 0.25% of their portfolio. Teacher Retirement Sys Of Texas reported 16,539 shares. Moreover, Deutsche Bank & Trust Ag has 0.02% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Stifel Fincl Corp has 18,343 shares. Glob X Ltd Liability Corp reported 208 shares. Regions Financial holds 0% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 85 shares. Bessemer Grp accumulated 0% or 81 shares. Wells Fargo & Mn owns 483,366 shares.

Since December 11, 2017, it had 0 buys, and 16 sales for $3.80 million activity. The insider COZADD BRUCE C sold 1,000 shares worth $150,000. MILLER MICHAEL PATRICK sold $30,224 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Wednesday, March 14. WILSON KAREN J also sold $604,345 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares. 877 shares were sold by Treacy Paul, worth $122,446. ENRIGHT PATRICK G also sold $1.26 million worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday, December 11.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 17 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Jazz Pharmaceuticals had 29 analyst reports since October 18, 2017 according to SRatingsIntel. BMO Capital Markets maintained the shares of JAZZ in report on Thursday, January 11 with “Buy” rating. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, November 8. As per Friday, November 10, the company rating was reinitiated by H.C. Wainwright. FBR Capital maintained it with “Buy” rating and $206.0 target in Wednesday, November 8 report. Cantor Fitzgerald maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Sunday, December 3 with “Buy” rating. BMO Capital Markets maintained the stock with “Outperform” rating in Wednesday, February 28 report. The company was maintained on Tuesday, January 30 by Piper Jaffray. FBR Capital initiated Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Wednesday, October 18 with “Buy” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, January 2. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, February 28. Below is a list of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) latest ratings and price target changes.

12/04/2018 Broker: Piper Jaffray Rating: Buy New Target: $201.0000 Maintain
06/04/2018 Broker: Seaport Global Rating: Buy New Target: $175.0000 Maintain
23/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $160.0000 Maintain
19/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade
16/03/2018 Broker: Leerink Swann Rating: Buy New Target: $180.0 Maintain
09/03/2018 Broker: FBR Capital Rating: Buy New Target: $206.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $202.0 Maintain
28/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $196 New Target: $199 Maintain
20/02/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $164 New Target: $170 Maintain
30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $194.0 Maintain

The stock increased 0.51% or $0.79 during the last trading session, reaching $156.75. About 154,990 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 0.32% since April 17, 2017 and is downtrending. It has underperformed by 11.87% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $9.37 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 19.69 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.